A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research”: RECONSIDERATION OF PARROTT MDMA REVIEW
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Parrott recently published a review of literature on MDMA/ecstasy. This commentary is a response to the content and tenor of his review, which mischaracterizes the literature through misstatement and omission of contrary findings, and fails to address the central controversies in the literature. The review makes several erroneous statements concerning MDMA-assisted psychotherapy, such as incorrect statements about research design and other statements that are baseless or contradicted by the literature. Though it critiques an attempt by other authors to characterize the risks of MDMA, the review fails to produce a competing model of risk assessment, and does not discuss potential benefits. Parrott does not represent an even-handed review of the literature, but instead recites dated misconceptions about neurotoxicity concerns involving the recreational drug ecstasy, which do not relate directly to the use of pure MDMA in a therapeutic setting. Unchallenged, Parrott's report may deter researchers from further investigating an innovative treatment that in early clinical trials has demonstrated lasting benefits for people with chronic, treatment-resistant post-traumatic stress disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 2×
“Parrott critiques a model for assessing the risks and benefits of recreational drugs (Nutt et al., 2007), but does not mention that an independent team of researchers in the Netherlands found that their own model, based on experts rating substances from fact sheets, often matched the ratings generated by Nutt’s model…”
BackgroundMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · cited 5×
“These surreal fabrications have never even remotely occurred in controlled trials of MDMA-assisted psychotherapy (Mithoefer et al., 2011; Mithoefer et al., 2013; Oehen et al., 2013).”
BackgroundInfluentialSubjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413 · cited 2×
“Parrott’s review mischaracterizes a quote from Greer and Tolbert’s report on MDMA-assisted psychotherapy (Greer and Tolbert, 1986), wherein, Parrott quotes only the last sentence of this section: (In full),”
BackgroundSelf-citationRanking the Harm of Alcohol, Tobacco and Illicit Drugs for the Individual and the Population
van Amsterdam, J., Opperhuizen, A., Koeter, M., & van den Brink, W. (2010) · European Addiction Research · doi:10.1159/000317249 · Cited by 191 · cited 1×
“…and benefits of recreational drugs (Nutt et al., 2007), but does not mention that an independent team of researchers in the Netherlands found that their own model, based on experts rating substances from fact sheets, often matched the ratings generated by Nutt’s model (van Amsterdam et al., 2010).”
Result
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“While some concerns may remain about possible neurotoxicity or adverse cognitive effects associated with chronic abuse of ‘Ecstasy’ (Parrott, 2013, 2014), such effects have not been observed in individuals undergoing limited exposure to pure MDMA in controlled settings (Doblin et al., 2014).”
BackgroundInfluentialPsychedelic medicine: a re-emerging therapeutic paradigm
Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141124 · Cited by 187
A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy
Sessa, B., Higbed, L., & Nutt, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00138 · Cited by 141
Sessa, B. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.004 · Cited by 97
Self-citation
Metadata
- Authors
- Doblin, R., Greer, G., Holland, J., Jerome, L., Mithoefer, M. C., & Sessa, B.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2014-03
- Volume
- 29
- Issue
- 2
- Pages
- 105-108
- ISSN
- 0885-6222 (ISSN-L)
- OpenAlex
- W1517515257
- Cited by
- 49
- References
- 4
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research”: RECONSIDERATION OF PARROTT MDMA REVIEW. https://app.cochat.ai/papers/10.1002/hup.2389
- The paper
- Doblin, R., Greer, G., Holland, J., Jerome, L., Mithoefer, M. C., & Sessa, B. (2014). A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research”: RECONSIDERATION OF PARROTT MDMA REVIEW. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.2389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.